All In Biotech

Drug Trial Radar · NCT06101134

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for Nivolumab + Relatlimab Fixed-dose Combination Subcutaneous Versus Nivolumab + Relatlimab Fixed-dose Combination Intravenous and Nivolumab Subcutaneous Versus Nivolumab Intravenous in Participants With Melanoma

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

100

Actual

Start

Nov 6, 2023

Primary completion

Apr 10, 2025

Study completion Dec 21, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.

Conditions

  • Melanoma

Interventions

  • relatlimab+nivolumabDrug

    Specified dose on specified days

  • relatlimab+nivolumab+rHuPH20Drug

    Specified dose on specified days

  • nivolumabDrug

    Specified dose on specified days

  • nivolumab+rHuPH20Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 DoseTime frame: Cycle 4 Day 1 (each cycle consist of 4 weeks)

Locations

31 sites in 5 countries. Site status is shown where the registry gives one.

  • Local Institution - 0007

    Anchorage, Alaska

  • Local Institution - 0013

    Phoenix, Arizona

  • Local Institution - 0010

    San Francisco, California

  • Local Institution - 0034

    Atlanta, Georgia

  • Local Institution - 0032

    Edgewood, Kentucky

  • Local Institution - 0028

    Albuquerque, New Mexico

  • Local Institution - 0037

    Edmonds, Washington

  • Local Institution - 0036

    Issaquah, Washington

  • Local Institution - 0030

    Seattle, Washington

  • Local Institution - 0005

    Concepción, Chile

  • Local Institution - 0015

    Las Condes, Santiago Metropolitan, Chile

  • Local Institution - 0023

    Holargos, Athens, Greece

  • Local Institution - 0008

    Piraeus, Greece

  • Local Institution - 0033

    Thessaloniki, Greece

  • Local Institution - 0019

    Thessaloniki, B, Greece

  • Local Institution - 0014

    Athens, I, Greece

  • Local Institution - 0029

    Marousi, I, Greece

  • Local Institution - 0026

    Naples, Italy

  • Local Institution - 0017

    Bergamo, BG, Italy

  • Local Institution - 0035

    Meldola, FC, Italy

  • Local Institution - 0018

    Milan, MI, Italy

  • Local Institution - 0012

    Padova, PD, Italy

  • Local Institution - 0021

    Roma, RM, Italy

  • Local Institution - 0004

    Torino, TO, Italy

  • Local Institution - 0020

    Badalona, Spain

  • Local Institution - 0027

    Cantabria, Spain

  • Local Institution - 0003

    San Pedro Alcántara, Málaga, Spain

  • Local Institution - 0006

    Seville, Spain

  • Local Institution - 0011

    Barcelona, B, Spain

  • Local Institution - 0022

    Barcelona, B, Spain

  • Local Institution - 0009

    Cartagena, MU, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.